

Announcement Summary

Entity name

TELEX PHARMACEUTICALS LIMITED

Announcement Type

New announcement

Date of this announcement

Friday September 25, 2026

The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

Shares issued under the Telix Employee Stock Purchase Plans. Refer to Employee Stock Purchase Plan Rules within Telix 2024 and 2025 Annual Report at <https://ir.telixpharma.com/filings/sec-filings> and 2025 AGM Notice of Meeting at <http://ir.telixpharma.com/financial-information/annual-reports>

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
TLX	ORDINARY FULLY PAID	1,645	25/09/2026

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of entity

TELEX PHARMACEUTICALS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ACN

Registration number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

25/9/2026

Part 2 - Type of Issue

2.1 The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

2.2 The +class of +securities to be quoted is:

Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS?

No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Shares issued under the Telix Employee Stock Purchase Plans. Refer to Employee Stock Purchase Plan Rules within Telix 2024 and 2025 Annual Report at <https://ir.telixpharma.com/filings/sec-filings> and 2025 AGM Notice of Meeting at <https://ir.telixpharma.com/financial-information/annual-reports>

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

Not applicable - the entity has arrangements in place with the holder that ensure the securities cannot be on-sold within 12 months in a manner that would breach section 707(3) or 1012C(6)

Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description

TLX : ORDINARY FULLY PAID

Issue date

25/9/2026

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Issue details

Number of +securities to be quoted

1,645

Are the +securities being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid? What is the issue price per +security?

USD - US Dollar

USD 6.47700000

Any other information the entity wishes to provide about the +securities to be quoted

The purpose(s) for which the entity is issuing the securities

Other

Please provide additional details

1,645 shares issued which will be distributed to the Telix US depository bank and allocated to US employees as American Depository Shares (ADS) under the Telix Employee Stock Purchase Plan (ESPP). Refer to ESPP Rules within Telix 2024 and 2025 Annual Report (on Form 20-F) at <https://ir.telixpharma.com/filings/sec-filings> and 2025 AGM Notice of Meeting at <https://ir.telixpharma.com/financial-information/annual-reports>. ADS allocated will be restricted from trade or transfer until April 2028

Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
TLX : ORDINARY FULLY PAID	339,894,019

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLXAY : DEFERRED SHARE RIGHTS	66,140
TLXAX : DEFERRED SHARE RIGHTS EX-US	87,649
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	15,000
TLXAZ : SHARE RIGHTS US	456,742
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,171,000
TLXAO : SHARE APPRECIATION RIGHTS	15,391,074
TLXAT : CONVERTIBLE NOTES	6,250
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAU : DEFERRED SHARE RIGHTS EX-US 2024	6,575
TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	8,555,838
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000

Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13